tetano
Editor, Senior Moderator
Dent Mater
. 2022 Mar 14;S0109-5641(22)00070-7.
doi: 10.1016/j.dental.2022.03.005. Online ahead of print.
Verification of lateral flow antigen tests for SARS-CoV-2 by qPCR directly from the test device
Ludwig Czibere[SUP] 1 [/SUP], Siegfried Burggraf[SUP] 1 [/SUP], Marc Becker[SUP] 2 [/SUP], Jürgen Durner[SUP] 3 [/SUP], Miriam E Draenert[SUP] 4 [/SUP]
Affiliations
Abstract
Objective: Fast and reliable detection of infection is a key to control the SARS-CoV-2 pandemic. Lateral flow antigen tests (LFATs) are inexpensive, easy to use, but have to be verified, as they are rather unspecific and can produce both, false positive and false negative results. Our objective was to combine the speed of LFAT for SARS-CoV-2 with the reliability of qPCR tests.
Methods: A serial dilution of a patient sample positive for SARS-CoV-2 was prepared and added to LFAT wells from two manufacturers. After evaluation, the devices were opened, the strips removed and extracted in a solution. Amplification was performed using point of care PCR systems (cobas® Liat®, ID NOW™) or on a LightCycler after extraction by MagNAPure 96.
Results: The nucleic acid amplification systems yielded higher sensitivity to LFAT. Thus, all samples determined positive by LFAT from the serial dilution were also positive in the subsequent amplification reactions. Sensitivity using extracted eluates was 10-100 times higher.
Significance: The usage of LFAT is highly recommended for single samples in emergency dental or emergency clinical settings, for smaller cohorts, or even for larger population screening, as it is inexpensive and fast. Positive results can be conveniently verified directly from the test devices using either point of care test equipment or more complex laboratory equipment thus making a major impact on efficient management of infections and isolations.
Keywords: Cobas Liat; Coronavirus; Dental clinical safety; ID Now; Lateral flow antigen test (LFAT); QPCR; Rapid antigen tests; SARS-CoV-2; Test strategy.
. 2022 Mar 14;S0109-5641(22)00070-7.
doi: 10.1016/j.dental.2022.03.005. Online ahead of print.
Verification of lateral flow antigen tests for SARS-CoV-2 by qPCR directly from the test device
Ludwig Czibere[SUP] 1 [/SUP], Siegfried Burggraf[SUP] 1 [/SUP], Marc Becker[SUP] 2 [/SUP], Jürgen Durner[SUP] 3 [/SUP], Miriam E Draenert[SUP] 4 [/SUP]
Affiliations
- PMID: 35307210
- DOI: 10.1016/j.dental.2022.03.005
Abstract
Objective: Fast and reliable detection of infection is a key to control the SARS-CoV-2 pandemic. Lateral flow antigen tests (LFATs) are inexpensive, easy to use, but have to be verified, as they are rather unspecific and can produce both, false positive and false negative results. Our objective was to combine the speed of LFAT for SARS-CoV-2 with the reliability of qPCR tests.
Methods: A serial dilution of a patient sample positive for SARS-CoV-2 was prepared and added to LFAT wells from two manufacturers. After evaluation, the devices were opened, the strips removed and extracted in a solution. Amplification was performed using point of care PCR systems (cobas® Liat®, ID NOW™) or on a LightCycler after extraction by MagNAPure 96.
Results: The nucleic acid amplification systems yielded higher sensitivity to LFAT. Thus, all samples determined positive by LFAT from the serial dilution were also positive in the subsequent amplification reactions. Sensitivity using extracted eluates was 10-100 times higher.
Significance: The usage of LFAT is highly recommended for single samples in emergency dental or emergency clinical settings, for smaller cohorts, or even for larger population screening, as it is inexpensive and fast. Positive results can be conveniently verified directly from the test devices using either point of care test equipment or more complex laboratory equipment thus making a major impact on efficient management of infections and isolations.
Keywords: Cobas Liat; Coronavirus; Dental clinical safety; ID Now; Lateral flow antigen test (LFAT); QPCR; Rapid antigen tests; SARS-CoV-2; Test strategy.